Printer Friendly
The Free Library
4,547,560 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Corporate Profile for DepoMed Inc., dated Feb. 7.


--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. .

These include Dow Jones Dow Jones

the best known of several U.S. indexes of movements in price on Wall Street. [Am. Hist.: Payton, 202]

See : Finance
 News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine See AOL. , CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International
UMI United States Minor Outlying Islands (ISO Country code)
UMI University of Miami
UMI Universal Management Infrastructure (IBM) 
 Data Courier, NewsBank, Information Access Company, Prodigy An online information service that provides access to the Internet, e-mail and a variety of databases. Launched in 1988, Prodigy was the first consumer-oriented online service in the U.S. , Comtex, and many others. -0-

Published Date:   Feb. 7, 1997

Company Name:     DepoMed Inc.

Address:          1170 B Chess Drive
                  Foster City, CA  94404-1167

Main Telephone
 Number:          415/513-0990

Chief Executive
 Officer:         John W. Fara, Ph.D.

Chief Financial
 Officer:         John F. Hamilton

Investor Relations
 Contact:         John F. Hamilton
 Business number: 415/513-0990

Public Relations
 Contact:         John F. Hamilton
 Business number: 415/513-0990

Industry:         Drug delivery





Company description: DepoMed Inc. is headquartered in Foster City, Calif., near San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden . Its mission is to develop new, proprietary drug delivery technologies and innovative products based on these technologies. To date DepoMed has developed two separate oral drug delivery systems. Each has received extensive patent coverage. The technologies provide for:

Reduced Irritation

The "DepoMed RI System" provides for significant reduction in the GI irritation of drugs with this side effect. As an example, in a standard model for GI irritation, the irritant ir·ri·tant
adj.
Causing irritation, especially physical irritation.

n.
A source of irritation.


irritant,
n 1. an agent that causes an irritation or stimulation.
2.
 properties of aspirin were reduced by 72% when delivered in the DepoMed system. The drug candidate list for this system is extensive.

Gastric Retention

The "DepoMed GR System" is designed to be retained in the stomach for a multi-hour period, during which time the incorporated drug is released in a continuous, controlled manner. The GR System is expected to allow for unprecedented effectiveness in the treatment of local stomach disorders and for drugs which are preferentially absorbed in the stomach.

Corporate Partnering

In mid 1996, DepoMed signed two product development agreements: one with a U.S. biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 company and one with a major, multi-national pharmaceutical company. The company is actively seeking additional corporate alliances.

CONTACT: DepoMed Inc.
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 7, 1997
Words:337
Previous Article:Corporate Profile for SurfSoft Internet Engineering, dated Feb. 7, 1997.
Next Article:Corporate Profile for Sionix Corp., dated Friday, Feb. 7, 1997.
Topics:



Related Articles
DepoMed Announces New President and CEO, and Appoints Chief Financial Officer.
DepoMed, Inc. Completes $8 Million Private Placement.
Depomed Adds Peter Staple to Board of Directors.
Depomed To Present at The Roth Capital Partners 16th Annual Growth Stock Conference.
DEPOMED/MADAUS SIGN PACT FOR PROQUIN XR IN EUROPE.
Depomed Promotes Bret Berner, Ph.D. to Chief Scientific Officer.
Depomed Gains Greater Access to Global Pharmaceutical Companies Through Collaboration Agreement with Patheon; The Company Expands Reach to Maximize...
Depomed Announces Completion of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned.
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology.
Research and Markets: Get the Latest Information Available on DepoMed Inc's Current Pipeline Portfolio.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles